

ISPOR Europe 2024




November 19, 2024, Barcelona, Spain Budget Impact of Intravenous Eptinezumab in the Prevention of **Chronic Migraine Patients in United Arab Emirates**


Mariam Mohammed Elattar^{1*}, Tamer Zidan², Saima Saeed³, Gihan Hamdy Elsisi^{1,4} ¹HEOR Department, HTA Office, Middle East and North Africa, ²Neurology Department, Zahra Hospital, Dubai, Emirates, ³Pharmacy Department, Al-Ain Hospital, Al-Ain, Emirates, ⁴Faculty of Economics, American University in Cairo, Egypt

¶≣

• Our research aimed to assess the potential budget changes upon introducing a preventive new Eptinezumab, for chronic treatment, migraine



• A budget impact model was developed to assess Eptinezumab gradually replaced galcanezumab,





Results:

- The base case results for our target population showed that the future scenario resulted in total PPPM drug costs of AED1,913 and the total PPPM non-drug costs were AED7,820.
- The total PPPM drug costs of the current scenario (without eptinezumab) were AED1,869 while the total PPPM non-drug costs were AED8,252.
- The PPPM total drug costs, PPPM total non-drug costs saving and PPPM total budget saving over 3 years were AED43.92, -AED432.03 and -AED 388.10, respectively.
- The total budget saving for the Emirati target population were -AED2,335,049,915 over 3 years.

Introducing eptinezumab into the treatment plan for chronic migraine patients in UAE who have not responded to two or more preventive therapies over a three-year period led to substantial budget savings.

- Deptinezumab resulted in cost savings in non-drug medical expenses due to reduced frequency of migraine attacks, fewer adverse events, and lower productivity loss.
- Despite the upfront drug costs of eptinezumab, these were offset by the savings from reduced migraine management and productivity loss.

*Address correspondence to: Mariam Mohammed Elattar Research Director, HEOR Department, HTA Office, Middle East and North Africa, Cairo, Egypt (Mariam.attar@htaoffice.com) Acknowledgment: Fady Abdelmalek, PharmB, HEOR Specialist, HTA Office, Middle East and North Africa